Replicate Bioscience, Inc. — Form D/A
Replicate Bioscience, Inc. of SAN DIEGO, CA, a company, filed a Form D amendment with the SEC on 2022-03-09. The offering totals $53.0M, of which $20.0M was reported sold. Industry: Biotechnology.
Offering
- Filed: 2022-03-09
- Form: D/A
- Accession: 0001846344-22-000001
- Industry: Biotechnology
- Exemptions: 06b
- Total offering: $53.0M
- Amount sold: $20.0M
- Remaining: $33.0M
- Investors: 1
- Date of first sale: 2021-02-04
- Security types: equity
- Revenue range: Decline to Disclose
- SEC file number: 021-389517
Issuer
- Name: Replicate Bioscience, Inc.
- CIK: 0001846344
- Entity type: Corporation
- Jurisdiction: DELAWARE
- Incorporated: 2021
- Address: 10210 CAMPUS POINT DRIVE, SAN DIEGO, CA, 92121
- Phone: 619-786-7702
Officers, directors & promoters (6)
| Name | Role | Location |
|---|
| Michael Ehlers | Director | Morristown, NJ |
| Seth Harrison | Director | Redwood City, CA |
| Nathaniel Wang | Director | San Diego, CA |
| Joseph Yanchik | Director | San Diego, CA |
| Michael Ehlers | Executive Officer | Morristown, NJ |
| Nathaniel Wang | Executive Officer | San Diego, CA |
Other filings by this issuer (1)
More